FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3001645249> ?p ?o ?g. }

• W3001645249 endingPage "S141" @default.
• W3001645249 startingPage "S140" @default.
• W3001645249 abstract "BackgroundPericardial effusion (PE) is a rare but life-threatening complication that can occur following hematopoietic stem cell transplant (HCT). The incidence in pediatric post-HCT population has been reported to be between 9%-37%. The underlying etiology is unclear and small studies have reported high morbidity and mortality in patients who develop PE post-HCT. Various studies have attempted to analyze the risk factors associated with occurrence of PE after HCT but detailed analysis is limited due to low incidence.MethodsWe retrospectively analyzed the University of Minnesota's Blood and Marrow Transplant database for occurrence of PE after HCT in patients less than 18 years between January 1, 2005 and December 31, 2018. Data was analyzed to compare the overall survival (OS) in patients who developed PE with those who did not. Risk factors analyzed included age, graft versus host disease (GVHD), type of conditioning regimen, graft source, underlying disease and human leukocyte antigen matching using univariate analysis. Multivariate analysis was performed using logistic regression model.ResultsA total of 770 patients underwent HCT during the study period, of which 162 (21%) developed PE. The median age of transplant for patients who developed PE was 8 years with about 60% males (n=98). Median time to development of PE after HCT was 69 days. Children who developed PE post-HCT had a significantly poor survival (2-year OS of 66%, confidence interval (CI): 58-73% vs 78%, CI: 75-81% in controls; p<0.01). There was a higher risk of grade III-IV acute GVHD in the PE cohort (relative risk (RR) of 14% (CI: 8-19%) vs 4%(CI: 3-6%) in those without PE). In univariate analysis, use of myeloablative conditioning as compared to non-myeloablative or reduced intensity conditioning (RR of 24% (CI: 20-27%) vs 11% (CI: 7-16%); p<0.01), use of umbilical cord blood (UCB) stem cells compared to bone marrow or peripheral blood stem cells (RR: 24% (CI: 20-28%) vs 18% (CI: 14-21%); p<0.01), and underlying malignant disorders were significantly associated with development of PE (RR: 26% (CI: 20-31%)) and inherited metabolic disorders (RR: 23% (CI: 17-28%) vs 15% in non-malignant disorders (CI: 11-20%); p<0.01). A higher risk was also noted in those with metabolic disorders (In multivariate analysis, use of myeloablative conditioning showed a significantly higher risk of development of PE (hazard ratio of 2.16 (CI: 1.33-3.50); p<0.01).ConclusionPericardial effusion after HCT is associated with a higher mortality and higher risk of severe acute GVHD. The high-risk group (underlying malignancy, receiving myeloablative conditioning and UCB transplant) should be monitored closely for development of PE. Pericardial effusion (PE) is a rare but life-threatening complication that can occur following hematopoietic stem cell transplant (HCT). The incidence in pediatric post-HCT population has been reported to be between 9%-37%. The underlying etiology is unclear and small studies have reported high morbidity and mortality in patients who develop PE post-HCT. Various studies have attempted to analyze the risk factors associated with occurrence of PE after HCT but detailed analysis is limited due to low incidence. We retrospectively analyzed the University of Minnesota's Blood and Marrow Transplant database for occurrence of PE after HCT in patients less than 18 years between January 1, 2005 and December 31, 2018. Data was analyzed to compare the overall survival (OS) in patients who developed PE with those who did not. Risk factors analyzed included age, graft versus host disease (GVHD), type of conditioning regimen, graft source, underlying disease and human leukocyte antigen matching using univariate analysis. Multivariate analysis was performed using logistic regression model. A total of 770 patients underwent HCT during the study period, of which 162 (21%) developed PE. The median age of transplant for patients who developed PE was 8 years with about 60% males (n=98). Median time to development of PE after HCT was 69 days. Children who developed PE post-HCT had a significantly poor survival (2-year OS of 66%, confidence interval (CI): 58-73% vs 78%, CI: 75-81% in controls; p<0.01). There was a higher risk of grade III-IV acute GVHD in the PE cohort (relative risk (RR) of 14% (CI: 8-19%) vs 4%(CI: 3-6%) in those without PE). In univariate analysis, use of myeloablative conditioning as compared to non-myeloablative or reduced intensity conditioning (RR of 24% (CI: 20-27%) vs 11% (CI: 7-16%); p<0.01), use of umbilical cord blood (UCB) stem cells compared to bone marrow or peripheral blood stem cells (RR: 24% (CI: 20-28%) vs 18% (CI: 14-21%); p<0.01), and underlying malignant disorders were significantly associated with development of PE (RR: 26% (CI: 20-31%)) and inherited metabolic disorders (RR: 23% (CI: 17-28%) vs 15% in non-malignant disorders (CI: 11-20%); p<0.01). A higher risk was also noted in those with metabolic disorders (In multivariate analysis, use of myeloablative conditioning showed a significantly higher risk of development of PE (hazard ratio of 2.16 (CI: 1.33-3.50); p<0.01). Pericardial effusion after HCT is associated with a higher mortality and higher risk of severe acute GVHD. The high-risk group (underlying malignancy, receiving myeloablative conditioning and UCB transplant) should be monitored closely for development of PE." @default.
• W3001645249 created "2020-01-30" @default.
• W3001645249 creator A5008157848 @default.
• W3001645249 creator A5009075765 @default.
• W3001645249 creator A5009195619 @default.
• W3001645249 creator A5033661466 @default.
• W3001645249 creator A5047421167 @default.
• W3001645249 creator A5051468151 @default.
• W3001645249 creator A5072526855 @default.
• W3001645249 creator A5076642923 @default.
• W3001645249 creator A5079500075 @default.
• W3001645249 date "2020-03-01" @default.
• W3001645249 modified "2023-09-26" @default.
• W3001645249 title "Pericardial Effusion after Hematopoietic Stem Cell Transplant Is Associated with Poor Survival" @default.
• W3001645249 doi "https://doi.org/10.1016/j.bbmt.2019.12.668" @default.
• W3001645249 hasPublicationYear "2020" @default.
• W3001645249 type Work @default.
• W3001645249 sameAs 3001645249 @default.
• W3001645249 citedByCount "0" @default.
• W3001645249 crossrefType "journal-article" @default.
• W3001645249 hasAuthorship W3001645249A5008157848 @default.
• W3001645249 hasAuthorship W3001645249A5009075765 @default.
• W3001645249 hasAuthorship W3001645249A5009195619 @default.
• W3001645249 hasAuthorship W3001645249A5033661466 @default.
• W3001645249 hasAuthorship W3001645249A5047421167 @default.
• W3001645249 hasAuthorship W3001645249A5051468151 @default.
• W3001645249 hasAuthorship W3001645249A5072526855 @default.
• W3001645249 hasAuthorship W3001645249A5076642923 @default.
• W3001645249 hasAuthorship W3001645249A5079500075 @default.
• W3001645249 hasBestOaLocation W30016452491 @default.
• W3001645249 hasConcept C120665830 @default.
• W3001645249 hasConcept C121332964 @default.
• W3001645249 hasConcept C126322002 @default.
• W3001645249 hasConcept C141071460 @default.
• W3001645249 hasConcept C144301174 @default.
• W3001645249 hasConcept C2777408962 @default.
• W3001645249 hasConcept C2908647359 @default.
• W3001645249 hasConcept C2911091166 @default.
• W3001645249 hasConcept C38180746 @default.
• W3001645249 hasConcept C44249647 @default.
• W3001645249 hasConcept C61511704 @default.
• W3001645249 hasConcept C71924100 @default.
• W3001645249 hasConcept C90924648 @default.
• W3001645249 hasConcept C99454951 @default.
• W3001645249 hasConceptScore W3001645249C120665830 @default.
• W3001645249 hasConceptScore W3001645249C121332964 @default.
• W3001645249 hasConceptScore W3001645249C126322002 @default.
• W3001645249 hasConceptScore W3001645249C141071460 @default.
• W3001645249 hasConceptScore W3001645249C144301174 @default.
• W3001645249 hasConceptScore W3001645249C2777408962 @default.
• W3001645249 hasConceptScore W3001645249C2908647359 @default.
• W3001645249 hasConceptScore W3001645249C2911091166 @default.
• W3001645249 hasConceptScore W3001645249C38180746 @default.
• W3001645249 hasConceptScore W3001645249C44249647 @default.
• W3001645249 hasConceptScore W3001645249C61511704 @default.
• W3001645249 hasConceptScore W3001645249C71924100 @default.
• W3001645249 hasConceptScore W3001645249C90924648 @default.
• W3001645249 hasConceptScore W3001645249C99454951 @default.
• W3001645249 hasIssue "3" @default.
• W3001645249 hasLocation W30016452491 @default.
• W3001645249 hasOpenAccess W3001645249 @default.
• W3001645249 hasPrimaryLocation W30016452491 @default.
• W3001645249 hasRelatedWork W2338961863 @default.
• W3001645249 hasRelatedWork W2380013293 @default.
• W3001645249 hasRelatedWork W2568237566 @default.
• W3001645249 hasRelatedWork W2767445481 @default.
• W3001645249 hasRelatedWork W2770409748 @default.
• W3001645249 hasRelatedWork W2948755618 @default.
• W3001645249 hasRelatedWork W3006783849 @default.
• W3001645249 hasRelatedWork W3030103226 @default.
• W3001645249 hasRelatedWork W3215105073 @default.
• W3001645249 hasRelatedWork W4293503962 @default.
• W3001645249 hasVolume "26" @default.
• W3001645249 isParatext "false" @default.
• W3001645249 isRetracted "false" @default.
• W3001645249 magId "3001645249" @default.
• W3001645249 workType "article" @default.